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Background: Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom palliation, maintenance
of quality of life (QoL) and prolongation of life are primary therapeutic goals.
Methods: Sixty-six UK oncologists completed an online survey about AOC management. Two hundred and two patients were
interviewed about care, treatment experiences and expectations.
Results: Prior to diagnosis, 34% (69 out of 202) of women hadX3 symptoms associated with AOC. Twenty-one per cent (43 out of
202) thought poor symptom recognition by general practitioners (GPs) delayed diagnosis. Amelioration of side effects
experienced was variable, for example, only 54% (68 out of 127) distressed by alopecia had received sufficient information about it.
Clinicians were asked ‘What minimum gain in progression-free survival (PFS) would make you feel it worthwhile to offer
maintenance therapy?’; 48% (24 out of 50) indicated 5–6 months, but 52% (26 out of 50) believed patients would find PFS of 3–4
months acceptable. When patients were presented with hypothetical scenarios, 33% (52 out of 160) would require 1–2 months
extra life, 6% (10 out of 160) 3–4 months, 31% (49 out of 160) 5–6 months, and 31% (49 out of 160) X7 months. However, 86%
(173 out of 202) would accept treatment that improved QoL without prolongation of life. When asked what was most important,
33% (67 out of 201) said QoL, 9% (19 out of 201) length of life and 57% (115 out of 201) said both were equally important.
Conclusion: Clinicians’ and patients’ experiences, expectations and priorities about OC management may differ.
Ovarian cancer (OC) is the fifth most common cancer in UK
women, affecting B6500 women a year (Cancer Research UK,
2012). It is primarily a disease of older, postmenopausal women,
and diagnosis and specialist referral is often delayed due to the
insidious/vague nature of the presenting symptoms. By the time
most women are diagnosed they have advanced disease
(Stages II–IV) and the outcomes of UK patients are still poorer
than in comparable countries (Coleman et al, 2011). However, five-
year survival has increased from 33% to 44% since 2001 in the UK
and deaths have fallen by a fifth (Cancer Research UK, 2012).
The National Institute for Health and Clinical Excellence
(NICE) technology appraisal guidance No. 55 (NICE, 2003)
recommends that paclitaxel in combination with a platinum-based
compound or platinum-based therapy alone are offered as part of a
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first-line treatment package that also includes maximal debulking
surgery for patients with advanced disease. However, despite
optimal primary therapy, recurrent disease is diagnosed in the
majority of patients within 5 years (du Bois et al, 2009). The choice
of subsequent therapy at the time of progression or at relapse is
dependent on the platinum-free interval. Options for platinum-
sensitive patients (46 months since last therapy) include
platinum combinations (with pegylated liposomal doxorubicin
hydrochloride (PLDH), paclitaxel and gemcitabine). For patients
with platinum-resistant disease (o6 months since last therapy),
options include PLDH, weekly paclitaxel, topotecan and etoposide.
Addition of other drugs, such as bevacizumab to chemotherapy
regimens has until very recently been predominantly limited to
clinical trial settings. In December 2011, the European Medicines
Agency (EMA) approved bevacizumab for use in combination with
carboplatin and paclitaxel chemotherapy, then continued as single-
agent maintenance therapy for a total of 15 months as a front-line
treatment for women with stage IIIB–IV OC. In England,
the National Institute for Clinical Excellence (NICE) is not due
to report on their evaluations of bevacizumab until the summer of
2013. Although clinical trials have shown 3–4-month improvement
in progression-free survival (PFS) (Burger et al, 2011; Perren et al,
2011) and evidence of improvement in overall survival (OS) for
poor-risk subgroups (Kristensen et al, 2011), the prolonged
maintenance phase of bevacizumab therapy, typically 8–12
months, and its cost may still prove to be a barrier to its adoption
within the NHS. With regards to the clinical management of OC,
there are few published data on variations in practice across the
UK. Maintaining quality of life (QoL) is the main goal for these
patients, together with symptom control and, if possible,
prolongation of life. Continued contact with specialist nurses
during maintenance treatment may be of benefit, in terms of
offering reassurance and timely and appropriate supportive care
(Cox et al, 2006; Cox et al, 2008).
The influence of social support and clinical outcome has recently
been recognised in women with ovarian cancer (Lutgendorf et al,
2012). A higher level of social attachment (i.e. the subjective
experience of close emotional bonds) is associated with survival
advantage, which has implications for support activities during
adjuvant cancer care and beyond. Some centres now use patient-
reported outcome (PROs) measures to help clinicians systematically
identify and address symptoms of concern to the patient, which
together with more traditional clinical objective measures, may lead
to better decision making and tailoring of treatment. For example,
adjusting chemotherapy dosing according to patient-reported
severity of symptoms (Basch and Abernethy, 2011). In addition,
patients may have different expectations about treatments and place
different values on outcomes from those of health-care professionals
(Meropol et al, 2008). They may have preferences about different
types of management plans available in terms of treatment and its
mode of delivery. Furthermore, health-care professionals may rate
their expectations of minimum gain in terms of OS and PFS
differently to what they believe their patients would consider. The
purpose of this study was to examine the experiences and preferences
of women with advanced OC for their care and treatment, and
consider these results in terms of oncologists’ current practice within
the UK.
PATIENTS AND METHODS
Clinician survey. All oncologists treating women with advanced
OC in the UK were invited to complete an online survey between
October and December 2011 about their current clinical practice
and views on managing women with advanced OC. This was prior
to the decision to accept bevacizumab for advanced OC onto the
priority list of the Cancer Drugs Fund (CDF) in England (The CDF
ends April 2013 and its future is uncertain).
To ensure that the invitation was comprehensively distributed,
the gynaecological lead clinician for every cancer network in
England, Wales, Scotland and Northern Ireland was contacted and
asked to supply contact details for oncologists treating women with
OC or to forward the invitation directly. Additionally, the British
Gynaecological Cancer Society alerted its membership by email
and provided a website link to the survey. The clinician survey
comprised five sections: (1) demographics: plus perceptions of
symptoms most troubling to women presenting with OC,
(2) routine NHS care for non-clinical trial patients: first-,
second-line and subsequent treatments, (3) maintenance therapy:
including opinions about minimum gain required for PFS and OS,
(4) clinical trial participation and (5) availability of supportive care
within their cancer centre/hospital.
Patient interviews. Women with stage II–IV OC recently
completed or currently receiving chemotherapy were eligible to
participate in the ADVOCATE (Advanced Ovarian Cancer: Care
and Treatment Experiences) study. Sixteen hospitals in England,
Scotland and Wales provided access to patients. Ethical approval
(ref: 11/LO/1527), sponsorship and all local NHS R&D permission
was obtained for each hospital.
Interview. Structured interviews were conducted by experienced
researchers (SC, VJ and LJF), and lasted between 30–45min.
Areas covered were: demography, medical/treatment history, co-
morbidities and medication, symptoms prior to diagnosis that
prompted medical help seeking, most ‘bothersome’ treatment side
effects and care received to ameliorate them, other support and
help provided, preferences for future treatment/care and patients’
views on maintenance therapy using a hypothetical scenario.
Standardised questionnaires. The European Organisation for
Research and Treatment in Cancer Quality Life Questionnaire
(EORTC QLQC30) (Aaronson et al, 1993) plus an ovarian cancer
module (OV28) (Greimel et al, 2003) were administered and the
EORTC INFO25 (Arraras et al, 2010) to record information needs.
These standardised measures require Likert-type responses: ‘not at
all’; ‘a little’; ‘quite a bit’; ‘very much’. Ratings are obtained
for individual items, for subscale scores and a global score. The
OV28 generates six symptom scales: abdominal/GI, peripheral
neuropathy, hormonal, body image, attitude to disease/treatment,
chemotherapy side effects and two additional items (other items
and sexuality). The INFO25 comprises four multi-item scales
(information about disease, medical tests, treatment and other
services) and eight single items.
Treatment records. With the patient’s consent, the gynaecology
teams provided a record of the treatments administered for
each woman.
Procedures. Eligible patients were invited to consider the study by
a member of the gynaecology team and given an information pack
to read. The pack contained a letter of invitation, a patient
information sheet, an expression of interest (EOI) form
and a prepaid return envelope. Those interested contacted the
researchers directly either by returning the EOI forms, by email or
telephone. Interviews were either conducted face to face or by
telephone, at a mutually convenient time. The QoL questionnaires
were completed during the same week as the interview and
returned by post. Written informed consent was obtained prior to
all data collection.
Statistical methods
Clinician survey and patient interviews. Summary statistics were
generated for the clinician and patient interview data including:
counts, percentages and means.
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Quality of life data and preferences. The global scores on the
EORTC QLQC30 and INFO25 questionnaires were analysed using
linear regression models. We dichotomised responses to questions
18 and 19 of the OV28 ‘hormonal’ scale so that ‘quite a bit/very
much’ indicated meaningful symptoms whereas ‘not at all/a little’
indicated no meaningful symptoms. We then fitted a logistic
regression model to the dichotomised responses. Similarly, we
fitted a logistic regression model to the ‘attitude’ scale items.
These analyses were adjusted for age group, on/off treatment,
partner/no partner and education. Responses to ‘Would you take a
drug that improved QoL but did not prolong life? (yes/no?)’ were
analysed using logistic regression models. We analysed the
responses to ‘Which is most important to you? (QoL, length of
life or both?)’ using a multi-nominal logistic regression to model
log-odds of preferring ‘QoL’ over ‘both’ and ‘length of life’
over ‘both’. Responses to the question ‘How many extra years
of life would make chemotherapy worthwhile? (‘1–2 months’,
‘3–4 months’, ‘5–6 months’ and ‘7 or more months’?)’, defined an
ordinal variable that was analysed using ordinal logistic regressions
to estimate the log-odds of a longer versus a shorter timespan
selected. These analyses were adjusted for QoL and INFO25 global
scores in addition to age group, on/off treatment, partner/no
partner and education.
Likelihood ratio tests were used for model selection, goodness
of fit was assessed and model diagnoses were carried out.
RESULTS
Clinicians and patients
Demography. There are no accurate records of how many UK
oncologists treat women with OC. However, the cancer network
gynaecology team leads believed the majority of treating oncolo-
gists were canvassed, and 66 out of 92 (70%) of them responded.
Table 1a shows the clinicians’ characteristics.
Clinic staff at the 16 centres distributed a total of
435 information packs to eligible patients; 225 out of 435 (52%)
patients returned EOI forms and 202 out of 225 (90%) were
interviewed. Mean time since diagnosis for participants was 31.5
months (s.d. 37 months). At the time of interview, 58% (117 out of
202) of women were receiving chemotherapy. Patients’ charact-
eristics including details of surgery are displayed in Table 1b.
Symptoms. Prior to diagnosis, 34% (69 out of 202) of women had
three or more symptoms that prompted a visit to their general
practitioner (GP); 31% (63 out of 202) had two symptoms, 29%
(59 out of 202) one symptom and 5% (11 out of 202) were
diagnosed incidentally. Primary symptoms were abdominal swel-
ling (53%; 108 out of 202), abdominal pain (38%; 78 out of 202)
and fatigue (20%; 41 out of 202), suggesting that advanced disease
was already present (see Figure 1). Oncologists ranked abdominal
pain/discomfort (33%; 22 out of 66), and abdominal swelling
(36%; 24 out of 66) as the most troublesome for patients at the time
of clinical presentation.
Patients made many comments about their experiences prior to
diagnosis and 21% (43 out of 202) were not satisfied about their
GP’s symptom recognition, believing this had led to a delay in
diagnosis. Women also felt there was a lack of awareness generally
in the public domain about ovarian cancer and its symptoms.
Quotes illustrating these two themes are shown in Appendix A.
Routine care and treatments. Oncologists indicated that the most
frequently used first-line treatment was carboplatin and paclitaxel
(86%; 56 out of 65), and fatigue was its commonest side effect
(55%; 36 out of 65). This was echoed in the patient survey where
70% (142 out of 202) of women receiving those drugs, cited both
fatigue (63%; 127 out of 202) and hair loss (63%; 127 out of 202) as
the most ‘bothersome’ side effects, followed by constipation (48%;
97 out of 202) (Figure 2).
The first-ranked trigger that influenced oncologists’ decisions to
initiate a second course of treatment was symptomatic disease
progression (75%; 49 out of 65). Second line and subsequent
treatments for platinum-sensitive patients was usually carboplatin
and paclitaxel (63%; 39 out of 62); for partially platinum-sensitive
patients, it was most often carboplatin with paclitaxel (3-weekly)
(40%; 25 out of 62); or carboplatin with PLDH (24%; 15 out of 62);
and PLDH was the treatment of choice for platinum-resistant
patients (68%; 42 out of 62). The majority of women interviewed
had received first- and second-line therapy (68%; 138 out of 202),
but 15% (31 out of 202) had received four or more courses of
chemotherapy (breakdown of chemotherapy regimens available
Supplementary Table A).
Clinicians reported that fatigue was the most complained about
and hardest to ameliorate side effect (50%; 31 out of 62); a finding
also reflected in the patient interviews. Although many women
were troubled by fatigue (63%; 127 out of 202), only 32% (40 out of
127) received any support or advice for this symptom. In contrast,
the majority of women (88%; 71 out of 81) concerned about their
symptoms of nausea received practical assistance, usually in the
form of anti-emetics. Helpful interventions were not so
Table 1a. Clinicians’ characteristics (n¼ 66)
Country
England 52 (79%)
Northern Ireland 1 (1%)
Scotland 8 (12%)
Wales 5 (8%)
Sex
Male 33 (50%)
Female 33 (50%)
Specialty
Medical oncologist 44 (67%)
Clinical oncologist 22 (33%)
Main place of work
Designated gynaecology cancer centre 51 (77%)
Cancer unit 12 (18%)
Other NHS hospital 3 (5%)
Main contract position
NHS Trust clinician 54 (82%)
University clinical academic 11 (17%)
Other 1 (1%)
Practice type
NHS only 36 (55%)
NHS and private 30 (45%)
Number of patients treated annually with advanced OC
(stages II–IV)
o30 14 (21%)
31–60 27 (41%)
460 25 (38%)
Clinical trials activity
Actively involved in clinical trials 59 (98%)
Conducts early phase trials 21 (35%)
Refers between 1–4 patients annually for early-phase trials 29 (73%)
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forthcoming for those ‘bothered’ by constipation 51% (49 out of
97). Worryingly, only 54% (68 out of 127) of women distressed by
hair loss said they received sufficient information as to when and
how their hair would fall out, and/or how to obtain an NHS wig.
When participants were grouped into (1) those with experience of
first-line therapy only (n¼ 61) and (2) those with experience of
second and subsequent chemotherapies (n¼ 141), the proportions
who reported troublesome side effects changed. Compared with
Group 2, women in Group 1 experienced more fatigue (72% vs
52%); constipation (69% vs 22%); and hair loss (66% vs 39%).
Clinical trial participation. Most clinicians were engaged in
clinical trials (98%; 59 out of 60), primarily ones in the NCRN
portfolio (97%; 57 out of 59), and some industry sponsored
(39%; 23 out of 59). Only 35% (21 out of 60) participated in
Phase 1 studies, the majority of whom (57%; 12 out of 21) enrolled
410 patients a year. Others (73%; 29 out of 40) referred between
1–4 patients to specialist centres for possible entry into early-phase
trials. Treatment forms from the centres indicated that overall 25%
(50 out of 202) of women in the patient survey had received OC
treatment within a clinical trial; 11% (23 out of 202) for first-line
therapy and 22% (28 out of 125) for second-line.
Follow-up. Regular clinical follow-up after a course of chemo-
therapy was reported by the majority of oncologists, (97%; 63 out
of 65), and 66% (43 out of 65) measured CA125 levels routinely
in clinic. Of those patients interviewed who were in follow-up
42% (85 out of 202), most reported attending clinics every 2 or 3
months (65%; 55 out of 85); CA125 blood level tests (69%; 59 out
of 85) were conducted more often than CT scans (20%; 17 out of
85). Satisfaction with follow-up care (scale: 0¼ not at all satisfied–
10¼ extremely satisfied) ranged between 2 to 10 with a mean of
Table 1b. Characteristics of patients (n¼ 202)
Age
Mean (s.d.) 63.5 years (9.6)
Min–Max 31–83 years
Education
Secondary (up to age 14–16 years) 107 (53%)
Further/higher 95 (47%)
Marital status
Married/civil partnership 132 (65%)
Single/divorced/separated/widowed 70 (35%)
Tumour stage
I (with progression) 5 (3%)
II 10 (5%)
III 121 (60%)
IV 64 (31%)
Unknown 2 (1%)
Time since diagnosis
Mean (s.d.) months 31.5 (37.0)
Min–Max months 1–233
Treatment
Surgery 175 (87%)
Radiotherapy 13 (6%)
Hormone therapy 23 (11%)
Total number of chemotherapy courses received
1 82 (41%)
2 56 (28%)
3 33 (16%)
4 17 (8%)
X5 14 (7%)
Ever received OC treatment within a trial 52 (26%)
Trials entered – mode (min–max) 1 (1–3)
Receiving chemotherapy at time of assessment 117 (58%)
Have comorbidity 141 (70%)
Surgery
No surgery attempted 15 (7%)
Biopsy only/exploratory laparotomy 2 (1%)
Awaiting surgery (after neo-adjuvant chemo) 10 (5%)
Primary debulking surgery 92 (46%)
Delayed primary debulking surgery (after neo-adjuvant
chemo)
83 (41%)
Surgery at relapse 16 (8%)
Hysterectomy prior to ovarian cancer 23 (11%)
Multiple symtoms could be reported
53.5 n =20238.6
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Abdominal swelling
Abdominal pain
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Loss of appetite
Urinary problems
Abnormal PV bleeding
Breathlessness
Bloating, rapidly full when eating
Constipation
Incidental (symptomless) diagnosis
Diarrhoea
Nausea/vomiting
Back pain
Worsening of IBS symptoms
Weight loss
Indigestion
Enlarged lymph nodes
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Excessive flatulance
Hip pain
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Figure 1. Distribution of symptoms prompting women to present
to GPs.
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Aching bones and joints
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Diarrhoea
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Insomnia
Severe vomiting
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Emotional disturbance
Anaemia
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Itching/skin rash
‘Fle-like’ hot and cold
General pain
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Blood clot
Breathlessness
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Dehydration
Bloating
Sore throat
Altered sense of smell
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Multiple side-effects could be reported
n =202
Figure 2. Distribution of the most bothersome side effects of first-line
chemotherapy
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8.64 (s.d. 1.9). Two centres did not offer follow-up and relied on
women to contact them if they had unmanageable symptoms.
Support. Oncologists rated the amount of support available in
their hospitals for patients in terms of personnel and information
services as high; with access to clinical nurse specialists (98%; 59
out of 60), information centres (93%; 56 out of 60), dieticians (87%;
52 out of 60) and psychologist/psychiatrists (80%; 48 out of 60).
Patients’ views on information resources and receipt of support
differed and depended on whether they were on or off active
treatment. For example, 14% (12 out of 85) of those off treatment
compared with 3% (3 out of 117) on treatment did not have any
contact with a specialist nurse. Also, 22% (19 out of 85) off
treatment had a telephone number for a nurse but never used it,
compared with 9% (11 out of 117) of women on treatment.
Patients’ most usual forms of support were family and friends
(69%; 139 out of 202) and GPs (58%; 117 out of 202), with only
32% (65 out of 202) relying on the hospital specialist nurse
(Figure 3).
There was close agreement that in-house material about
chemotherapy treatments was given to patients (oncologists 77%;
46 out of 60) (patients 78%; 158 out of 202). However, only 73%
(148 out of 202) of patients said that they had received Macmillan
booklets compared with clinicians (100%; 60 out of 60) who
reported that all patients are given them. The Macmillan Cancer
Support website was recommended by 92% (55 out of 60) of
oncologists and 49% (99 out of 202) of women said that they had
searched for information on OC independently, with 39% (79 out
of 202) using the internet; 14 out of 79 (18%) had viewed the
Macmillan site. Surprisingly few patients were aware of or had
received information from any of the ovarian cancer charities (6%;
12 out of 202).
Maintenance therapy. At the time of the clinician survey, only
three oncologists offered bevacizumab as maintenance therapy and
this was reflected in the patient treatment forms, where a minority
of patients (19%; 38 out of 202) had ever received maintenance
therapy and for 12 out of 38 patients (32%), this was within a
clinical trial. Thirteen oncologists also used endocrine therapies
(tamoxifen, letrozole and anastrozole) in ER-positive patients.
Twenty-three out of 202 (11%) women had received endocrine
treatment at some point, although not necessarily as maintenance
therapy.
A majority 50 out of 60 (83%) oncologists viewed maintenance
therapy positively albeit based on data regarding PFS benefits
shown in trials. There were interesting differences between the
minimum gains in PFS based on what the clinicians thought
worthwhile, compared with the gains they believed that their
patients would consider (see Table 2). All clinicians said that they
would feel more encouraged about offering maintenance therapy if
improvements in OS were shown.
At the interview, participants were presented with a hypothetical
scenario, asking: ‘If you were offered a drug that could prolong
your life, but it gave you side effects such as fatigue, feeling sick,
numbness or tingling in fingers and toes, how many extra months
of life would you want to make having the treatment worthwhile?’
Almost a quarter (21%; 42 out of 202) were unable/did not want
to give an answer to the question, a third (52 out of 160) said 1–2
months, 6% (10 out of 160) 3–4 months, 31% (49/160) 5–6
months, and 31% (49/160) X7 months (Table 3). However, when
asked: ‘If you were offered a drug that could improve your quality
of life but might not prolong it, would you be prepared to try it?’,
86% (173 out of 202) of women said they would be willing to try a
drug that improved their QoL even if it would not prolong their
life.
When asked what was the most important aim of treatment to
them, 33% (67 out of 201) said QoL, 9% (19 out of 201) length of
life and 57% (115 out of 201) said both were equally important.
QoL Questionnaire data. The mean global score on the EORTC
QLQC30 was 62.7 (s.d. 20.3); results for the subscales within this
measure are shown in Supplementary Table 4 together with scores
for the OV28 symptom scales alongside comparison scores of a
reference group from the EORTC manual. These scores show that
the sample were representative of women with advanced OC
disease. The QLC30 global score was lower (poorer QoL) in
women without a partner (b¼  5.9, P-value¼ 0.04), and those on
treatment (b¼  10.9, P-valueo0.001). Neither age group (under
and over 60 years) or education (secondary/higher) influenced the
global score.
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Figure 3. Distribution of support sources women relied upon.
Table 2. Maintenance therapy; PFS and OS survival
Months
Question
1–2
(%)
3–4
(%)
5–6
(%)
7þ
(%)
What minimum gain in PFS would
make you feel it worthwhile to offer
maintenance therapy? (n¼50)
0 19 (38) 24 (48) 7 (14)
What do you think your patient
would consider worthwhile? (n¼50)
12 (24) 26 (52) 9 (18) 3 (6)
What minimum gain in OS would
make you feel it worthwhile to offer
maintenance therapy? (n¼60)
2 (3) 36 (60) 15 (25) 7 (12)
What do you think your patient
would consider worthwhile? (n¼60)
25 (42) 23 (38) 5 (8) 7 (12)
Table 3. Patients views on maintenance therapy
N¼160 (42; 21%)
unable to answer
question 1–2 3–4 5–6 7þ
How many extra months life
would you want to make
having maintenance
treatment worthwhile?
52 (33%) 10 (6%) 49 (31%) 49 (31%)
N¼202 Yes No
Would you try a drug that
could improve the quality
of your life but might not
prolong it?
173 (86%) 19 (9%)
Quality of life Length
of life
Both
What is most important to
you? (1 missing)
67 (33%) 19 (9%) 115 (57%)
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The summary score from the OV28 symptom scales for the
hormonal items was influenced by age, with older women less
likely to report hot flushes (OR¼ 0.25, P-valueo0.001). Disease
was a burden to over 43% of patients, disease and treatment
burden were reported more often in those with higher education
(OR¼ 1.77, P-valueo0.049; OR¼ 2.7, P-valueo0.001
respectively).
Figure 4 shows the proportion of patients who responded ‘quite
a bit/very much’ to having received sufficient information about
the topics listed on the EORTC INFO25 questionnaire. Noticeably
X80% indicated that they had received adequate information on
diagnosis, disease extent, tests, treatments and side effects of
treatments. However, fewer women reported receiving sufficient
information about disease control (58%), how to cope at home
(40%), what help was available outside the hospital (40%) and
how to access psychological services (20%). The responses to
the information questionnaire were not influenced by age group,
on/off treatment, partner/no partner, or education.
Participants with a high global score on INFO25, those over
60 years and those with higher education levels were more likely to
cite QoL as more important (OR¼ 1.03, P¼ 0.02; (OR¼ 2.44,
P¼ 0.02 and (OR¼ 2.43, P¼ 0.011, respectively). When asked
‘How many extra months of life would you want to make having
maintenance treatment worthwhile?’, only global QoL score
influenced choice. Those with a lower (poorer) global EORTC
QLQ30 score (first quartile¼ 50) were more likely to want a
treatment to offer more time for it to be worthwhile (OR¼ 1.61,
P-value¼ 0.025) compared with those with a higher QoL score
(third quartile¼ 50).
DISCUSSION
These surveys provide a summary of oncologists’ treatment
practices across the UK and a comparison of their patients’
experiences. Many patients presented with late-stage disease with
abdominal pain and swelling. Almost a quarter were not satisfied
with the way their GP dealt with their concerns, often diagnosing
irritable bowel syndrome or constipation. These findings accord
with the Cancer Patient Experiences Survey 2011/12 (DoH 2012);
37% of ovarian cancer patients saw their GP more than twice about
their symptoms before being referred for diagnostic tests,
compared with just 8% of breast cancer patients. Our current
interviews also revealed patients felt strongly that there was a lack
of publicity about the signs and symptoms of ovarian compared
with breast and more recently lung cancer. One participant made a
salient point that some advertisers promote bloating or urinary
incontinence as quite normal for women over 50 years, and that
drinking/wearing certain products can help. Women often blamed
themselves for ignoring such symptoms, and consequently
presenting late at diagnosis when disease had spread.
Treatments offered across the UK were fairly similar. A large
proportion of oncologists were engaged in clinical trials and 26%
(52 out of 202) of patients interviewed had received OC treatment
within a trial; 12 out of 52 (23%) involved trials of maintenance
therapy. Fatigue was the most troublesome side effect for patients,
and clinicians acknowledged that it is difficult to treat. Patients
were aware of this and appreciated healthcare professionals’ (HCP)
advice and/or regular enquiry as to how they were coping.
It was noticeable that women who had received only one course
of chemotherapy reported side effects as being more troublesome
than did those who had experience of more than two further lines
of treatment. Intuitively this makes sense, as women might be
more prepared the second time and devised ways to cope with the
unwanted side effects. Although some centres offered an excellent
supportive service to women, with induction visits to the
chemotherapy suite, and discussing in detail the treatments and
side effects, others were lacking.
One surprising finding was that hair loss was not uniformly well
dealt with in terms of advice and wig-fitting. A significant
proportion of the women greatly disturbed by hair loss were
unprepared as to how and when their hair would fall out and/or
how and where to obtain a wig in the NHS. Providing a leaflet or
cursory mention that hair loss is an inevitable consequence
of treatment was not helpful for patients.
Patients’ views about information resources and receipt of
support differed from that reported by oncologists in the online
survey as available at their hospital/centre. Few women made use
of the specialist nurse during the period following the end of a
course of chemotherapy or at their follow-up appointment. Several
patients, no longer having active treatment expressed a feeling of
abandonment and felt a need for regular contact in the form of a
supportive telephone call. This was more noticeable in women
without a partner, who overall reported a poorer QoL. The
majority of women relied on family and friends for support.
The Cancer Patient Experiences Survey 2011/12 reported that
although 91% of ovarian cancer patients were given the name of
EORTC QLQ−INFO25 question
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the specialist nurse in charge of their care, only 68% said that she
was easy to contact. The survey also revealed that 40% of women
with ovarian cancer were not given written information about their
cancer (DoH 2012).
The information needs of the women we interviewed was met
for most of the tangible, practical aspects of treatment and care,
such as diagnosis, tests and treatments, but much less so for the
psychosocial aspects, such as whether the disease was under
control and how to cope at home. This is an area that needs greater
attention in view of the fact that maintaining quality of life,
together with symptom control is the main goal for these patients.
The majority of oncologists were positive about maintenance
therapy based on PFS benefits, but availability was a barrier to its
prescription. The clinician survey was conducted before the
decision to accept bevacizumab for advanced OC onto the priority
list of the Cancer Drugs Fund (CDF) in England, and few patients
interviewed had received the drug outside of a cilinical trial setting.
Patients’ views were similar to clinicians regarding OS, with 62%
requiring a gain of X5 months of life to make the treatment
worthwhile. It should be noted that PFS gains were not explored in
the patient interview as PFS is not a familiar term and rarely used
by clinicians when discussing treatments with patients (Fallowfield
and Fleissig, 2012).
Two previous studies have attempted to explore ovarian cancer
patients’ preferences for care, one focussed exclusively on patients’
choice regarding different first-line therapies (Elit et al, 1996), the
other examined treatment preferences in recurrent ovarian cancer,
tackling issues of quality and quantity of life (Donovan et al, 2002).
The latter found that on average patients would switch from
‘salvage therapy’ to palliative care when the median survival
associated with therapy was reduced to 5 months. There was no
association between any dimensions of QoL and the time point at
which patients would switch to palliative care. However, a
regression analysis showed that as family and friends’ involvement
increased, the period of survival associated with salvage therapy
women still found acceptable decreased. In the current study,
single women with poorer global QoL scores were more likely to
want a treatment to offer more time for it to be worthwhile than
those with higher QoL scores.
In our interviews, patients assumed maintenance therapy would
have similar toxicity to chemotherapy and it is possible that newer
biological agents with different side effects may change patients’
perceptions. Shorter timespan gains could be perceived as
worthwhile for therapies with less burdensome side effect profiles.
In the recent analysis of the ICON7 trial, QoL was measured using
the EORTC QLQ C30 and OV28. Results showed that bevacizu-
mab continuation treatment was associated with a small but
clinically significant decrement in Global QoL compared with
standard treatment (Stark et al, 2013). However, the authors note
that the Gynaecological Oncology Group (GOG 218) double-blind,
placebo control study used a different instrument for measuring
QoL (FACT O) and did not report a clinically important difference
between standard chemotherapyþ bevacizumab vs standard
chemotherapyþ placebo. They suggest that the difference between
the study results is because of disruption to women’s lives from
delivery of continuation therapy that was reflected in poorer role
functioning, financial worries, attitudes to disease to treatment,
hormonal symptoms and rash. A recent commentary on the
ICON7 trial advocates that women with ovarian cancer should be
asked to assess the inherent trade-offs implicated in new
treatments (Havrilesky and Abernethy, 2013).
Balancing QoL with the length of it was most important to 57%
(115 out of 201) of patients, another third (33%; 67 out of 201)
indicated that QoL was the priority, and for just 9% (19 out of 201)
length of life was paramount. This distribution is similar to a
previous report of preferences among patients with advanced
cancer where 55% (252 out of 459) equally valued QoL and length,
27% (123 out of 459) most valued QoL and 18% (84 out of 459)
length of life (Merepol et al. 2008).
Limitations of the study. Single time-point survey data are
sensitive to policy changes in relation to clinical practices and
we acknowledge this in relation to the use of bevacizumab.
Another limitation is that we are not directly matching the views
and practices of each oncologist that completed the clinician survey
with the views captured from patients they have necessarily treated.
However, by sampling from 16 hospitals in England, Scotland and
Wales, both large specialist cancer centres and small district
general hospitals, we hope to have gathered a good range of patient
experiences. We recognise that assuming maintenance therapy to
have toxicity equivalent to chemotherapy influences the extra-
polation of the patient preferences observed and further work is
needed to explore reactions to markedly different side effect profiles.
CONCLUSIONS
These UK surveys give a view of the treatments and care offered by
oncologists and received by women with advanced ovarian cancer.
Although the majority of women, once a diagnosis had been
established were happy with their care and treatment, a fair
proportion gave worrying reports of a lack of information and
support. These findings concur with much of the recent ovarian
cancer quality profile summaries produced from the National
Cancer Patient Experience Survey (CPES) for 2011/12. Increasing
women’s awareness of OC symptoms, together with earlier
diagnosis may help make this disease more treatable.
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APPENDIX A
Theme 1: delay in GP recognition of OC symptoms
‘The GP was hopeless, kept telling me I had constipation, I went
back many times and I knew I had something seriously wrong. In
the end I went to a private gynaecologist who did investigations
and scans that found the cancer’ ID70, 74 years
‘I went to the GP repeatedly with lower tummy pains before it
then started to swell, once that got bad the GP referred me for
investigations’ ID98, 61 years
‘GP took a long time to recognise that my symptoms were
something more serious than a urinary tract infection’ ID153, 83 years
‘I was going to the GP for more than a year reporting pain,
diarrhoea, weight loss, feeling full quickly when eating, it was
treated as irritable bowel syndrome’ ID163, 64 years
‘Very disappointed with the GP and the way my symptoms were
ignored and not investigated until it was all too late’ ID 184, 58 years
‘What made me mad was the GP, he didn’t listen to me when I
went to him, he just kept saying I had constipation, I knew I didn’t,
I now have a different GP’ ID 191, 46 years
Theme 2: general lack of awareness and good publicity about
symptoms of OC. ‘I feel I was never aware of ovarian cancer, I
had no idea about the signs and symptoms, it really, really needs to
be publicised, you hear lots about breast cancer’ ID05, 73 years
‘seeing adverts on TV and in magazines that tell women to eat
yoghurt for bloating makes me very angry and also the adverts that
say women commonly have urinary problems and should just buy
panty pads annoys me too’ ID30, 58 years
‘there needs to be much greater general awareness about ovarian
cancer in GPs’ surgeries, but also elsewhere for the public, like they
have for breast cancer or now they are making us more aware of
the lung cancer symptoms’ ID41, 70 years
‘Not enough general information at the GP surgery
about ovarian cancer, not enough awareness in general’ ID66,
66 years
‘I don’t think there is enough awareness about the illness
amongst women in general. There needs to be more information
and education, me and my friends had no idea about it, that I had
symptoms of it for probably a long time. There is a lot of ignorance
in women about the symptoms’ ID82, 72 years
‘My diagnosis came as a complete shock, not aware of ovarian
cancer, breast cancer is in the newspapers more’ ID141, 67 years
‘Ovarian cancer is not something that I know much about, don’t
know the symptoms, not publicised much, people don’t talk about
it’ ID148, 81 years
‘Breast cancer dominates in the news, lots of support and funds
raised. Ovarian cancer doesn’t seem to have the same sort of
impact. OC seems to be kept low key. Never much in the press.
Need to publicise it more’ ID178, 50 years
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